Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms Tumors

Amy L. Walz,Ariadne H.A.G. Ooms,Samantha Gadd,Daniela S. Gerhard,Malcolm A. Smith,Jaime M. Guidry Auvil,Daoud Meerzaman,Qing-Rong Chen,Chih Hao Hsu,Chunhua Yan,Cu Nguyen,Ying Hu,Reanne Bowlby,Denise Brooks,Yussanne Ma,Andrew J. Mungall,Richard A. Moore,Jacqueline E. Schein,Marco A. Marra,Vicki Huff,Jeffrey S. Dome,Yueh-Yun Chi,Charles G. Mullighan,Jing Ma,David A. Wheeler,Oliver Hampton,Nadereh Jafari,Nicole Ross,Julie M. Gastier-Foster,Elizabeth J. Perlman
DOI: https://doi.org/10.1016/j.ccell.2015.02.008
IF: 50.3
2015-01-01
Cancer Cell
Abstract:(Cancer Cell 27, 286–297; February 9, 2015) Dr. Jaime M. Guidry Auvil’s name was spelled incorrectly as “Jamie M. Guidry Auvil” in the original article. It appears correctly in this erratum, and the error has been corrected online. Recurrent DGCR8, DROSHA, and SIX Homeodomain Mutations in Favorable Histology Wilms TumorsWalz et al.Cancer CellFebruary 09, 2015In BriefWalz et al. identify recurrent SIX1, SIX2, DROSHA, and DGCR8 mutations in pre-therapy favorable histology Wilms tumors and find that mutant tumors more often have blastemal histology. Importantly, patients whose tumors have SIX1 or SIX2 mutations together with DROSHA or DGCR8 mutations have poorer survival. Full-Text PDF Open Archive
What problem does this paper attempt to address?